Archives for October 19, 2004

← 2004

Implantable RFID chip decision draws criticism

This week's announcement of the US approval for an implantable radiofrequency identification (RFID) chip for use in humans as a prescription device has been met with consternation by a consumer group, which fears the technology could infringe civil...

3M brings UK manufacturing license up to date

Drug developer 3M has been given the go ahead to manufacture, assemble and import investigational medicinal products (IMP) for clinical trials involving human use in the UK, writes Wai Lang Chu.

Technique set to improve drug design

Researchers in the US believe the discovery of a technique, which once applied to an enzyme that degrades anti-cancer drugs in humans, may improve such drugs' design and effectiveness.

New drug candidate for stroke makes progress

The road to a new treatment for stroke is littered with the remains of failed projects, so any data suggesting that a drug has activity in this indication should be greeted with cautious optimism at best. But AstraZeneca has joined those vying to...

Insmed trials encourage further cancer R&D

Biopharmaceutical company, Insmed, are to commence clinical development of a small molecule tyrosine kinase inhibitor, which has demonstrated anti-tumour activity in preclinical studies of breast, lung, pancreatic and prostate tumours.

Pumps as good as jabs in diabetic infants

Pre-school youngsters with type I diabetes can be treated as successfully with insulin pumps as with daily injections, researchers at the Indiana University School of Medicine report.

GSK Bio licenses preservative-free filling process

Belgium-based GlaxoSmithKline Biologicals has licensed a new production technology for its vaccines business that should do away with the need to use preservatives in the manufacturing process.

B-MS arthritis drug shows promise in Ph III

Bristol-Myers Squibb has reported encouraging data from two late-stage trials of a new drug for rheumatoid arthritis, abatacept, the first in a new class of T cell costimulation modulators.